Project Grant R50CA288482
Award Date 9/1/25
Completion Date 8/31/30
Dollars Obligated $179K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $216,682 to The Trustees of the University of Pennsylvania to develop "tumor-site activated T cell redirecting autoantibodies" - a novel cancer immunotherapy approach. The award period runs from March 1, 2025 to February 28, 2027. The project aims to leverage a patient's own anti-tumor autoantibodies to enhance the immune system's ability to target and clear cancer cells,...
- The National Cancer Institute (NCI) awarded a $619,628 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania. The funding will support the development and validation of an autologous mouse model to study immune system interactions with glioblastoma, a type of brain cancer. The goal is to create a humanized mouse system that incorporates patient-derived tumor...
- This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of next-generation CAR-T cell therapies for renal cell carcinoma (RCC). The award recipient, Cellinfinity Bio Inc., is developing novel CAR-T cell modifications, including a PRDM1 exon 3 knockout and a CTLA-4 cytoplasmic tail fusion, to enhance CAR-T cell efficacy against RCC tumors. The project aims to evaluate the combination of these...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,000.00 to Mayo Clinic to conduct research aimed at enhancing the effectiveness of immune checkpoint blockade (ICB) immunotherapy for renal cell carcinoma (RCC). The project seeks to demonstrate that disrupting the ubiquitination or phosphorylation of the RIPK1 protein in RCC tumor cells can increase their susceptibility to killing by T cells in a TNF-dependent manner, thereby...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The Trustees of the University of Pennsylvania to support the development and implementation of NCI-sponsored clinical trials for rare cancers. The $122,610 award, which began in August 2025, aims to: Assist junior and mid-career oncology faculty in developing investigator-initiated studies, and Develop a program within the National Clinical Trials Network (NCTN) to design...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,847,485 Project Grant to The University of Texas MD Anderson Cancer Center to advance next-generation CAR-NK (chimeric antigen receptor-modified natural killer) cell therapies targeting CD5-positive T-cell malignancies. The award, effective September 19, 2025 through August 31, 2029, will support the development and clinical testing of an engineered CAR-NK cell product expressing an anti-CD5 scFv, IL-15 for...
- This $483,395 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports research by The Institute For Cancer Research (ICR) to investigate targeting the P300/CBP proteins as a novel therapeutic approach for renal cell carcinoma (RCC). The key objectives are to examine the therapeutic potential of inhibiting P300/CBP in clear cell RCC, and establish the association between P300/CBP expression and disease progression, drug-resistance, and...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Dana-Farber Cancer Institute (DFCI) to investigate targeting the CDK4/6 pathway as a potential therapeutic strategy for translocation renal cell carcinoma (TRCC), an aggressive form of kidney cancer. The $267,298 award, effective from February 1, 2025 to January 31, 2027, will support in vitro and in vivo studies to test the sensitivity of TRCC cells to CDK4/6 inhibition,...
- The National Cancer Institute (NCI) awarded a $712,735 Project Grant under the Cancer Treatment Research (CFDA 93.395) program to the University of Southern California (USC) on June 1, 2025. This grant will fund a Phase II clinical trial to evaluate the efficacy of a combination therapy using the novel agent SEPHB4-HSA, an EphrinB2 inhibitor, and the PD-1 antibody Pembrolizumab in urothelial carcinoma (bladder cancer) patients whose tumors express EphrinB2 and have low/non-expressing Nectin4...
- The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...